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Abstract
Background: Atropine has is currently recommended to facilitate haemodynamic stability during critical care intubation.
Our objective was to determine whether atropine use at induction influences ICU mortality.
Methodology/Principal Findings: A 2-year prospective, observational study of all first non-planned intubations, September
2007–9 in PICU and Intensive Care Transport team of Hoˆpital Robert Debre´, Paris, 4 other PICUs and 5 NICUs in the Paris
Region, France. Follow-up was from intubation to ICU discharge. A propensity score was used to adjust for patient specific
characteristics influencing atropine prescription. 264/333 (79%) intubations were included. The unadjusted ICU mortality
was 7.2% (9/124) for those who received atropine compared to 15.7% (22/140) for those who did not (OR 0.42, 95%CI 0.19–
0.95, p = 0.04). One child died during intubation (1/264, 0.4%). Two age sub-groups of neonates (#28 days) and older
children (.28 days, ,8 years) were examined. This difference in mortality arose from the higher mortality in children aged
over one month when atropine was not used (propensity score adjusted OR 0.22, 95%CI 0.06–0.85, p = 0.028). No effect was
seen in neonates (propensity score adjusted OR 1.3, 95%CI 0.31–5.1 p = 0.74). Using the propensity score, atropine
maintained the mean heart rate 45.9 bpm above that observed when no atropine was used in neonates (95%CI 34.3–57.5,
p,0.001) and 43.5 bpm for older children (95%CI 25.5–61.5 bpm, p,0.001).
Conclusions/Significance: Atropine use during induction was associated with a reduction in ICU mortality in children over
one month. This effect is independent of atropine’s capacity to attenuate bradycardia during intubation which occurred
similarly in neonates and older children. This result needs to be confirmed in a study using randomised methodology.
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Introduction
Critical care intubation (CCI) of young children in critical care
situations represents a crucial moment in an episode of critical
illness and may be associated with cardiorespiratory decompen-
sation. In critically-ill adults the risk of death during CCI has been
estimated at 1–3% with pre-existing hypotension greatly increas-
ing this risk. [1,2] In children intubation mortality is lower. No
deaths were observed in either of two retrospective studies of 137
intubations in 103 children outside the Operating Room [3] and
or 143 children in the Emergency Department [4].
Paediatric anaesthetists and intensivists have used slowing of the
heart rate in children as a measure of haemodynamic stability
during CCI for more than 50 years. Two distinct mechanisms
contribute to falls in heart rate during intubation; the direct effects
of some induction drugs, and vagally-mediated parasympathetic
cholinergic inhibition of sino-atrial node activity as a reflex
response to hypoxaemia and/or laryngeal stimulation [5].
Atropine was proposed in the 1950s to overcome the anti-
cholinergic effects of suxamethonium during induction and
intubation. [6] Its efficacy in attenuating falls in heart rate during
anaesthetic intubation in children is proven. [7,8] Following the
introduction of non-depolarising muscle relaxants and less cardio-
depressant anaesthetics, such as sevoflurane, there has been a
decline in atropine use [9].
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Atropine is currently recommended to optimise haemodynamic
stability during CCI. [10] The 2007 American College of Critical
Care Medicine clinical practice parameters for hemodynamic
support in paediatric septic shock provide a level III (expert
opinion) recommendation for ‘‘Ketamine and atropine pretreatment
…[to] be used as an …induction regimen of choice to promote cardiovascular
integrity’’. [11] The lack of prospective data on the impact of
atropine on heart rate and outcome in critically ill children
prompted this study.
Our objective was to measure the effect of atropine use on ICU
mortality in a prospectively-recruited population of children
undergoing their first CCI. We assumed the null hypothesis that
atropine had no effect on either outcome. A propensity score was
used to adjust for patient specific prognostic characteristics that
might have influenced atropine prescription.
Methods
Study Design and Population
The study was multi-centre, prospective, observational and used
a propensity score to adjust for atropine use. An information letter
was provided for parents describing the objective of the study and
giving them the possibility of removing their child from the study.
The process was not documented. Written consent was not
obtained as the study did not involve intervention to the process of
intubation. This procedure is in accordance with French law and
was approved by the Comite´ d’Ethique et d’Evaluation en
Recherche Biome´dicale of the Groupe Hospitalo-Universitaire-
Paris Nord.
The ECG recordings were made in the Paediatric Intensive
Care Unit (PICU) and by the Paediatric/Neonatal Intensive Care
Transport Service (ICT) of the l’Hoˆpital Robert Debre´, Paris,
France, between September 2007 and September 2009. Children
were intubated by the ICT Team and transported to four
participating PICUs (Robert Debre´, Kremlin-Biceˆtre, Necker and
Trousseau Hospitals) and five Neonatal ICUs (Robert Debre´,
Creteil, Institut de Pue´riculture, Montreuil and Port Royal
Hospitals) in the Paris Region. Intubation ‘for transport’ is not
practised by the ICT Team.
All children who were undergoing their first non-elective
intubation and were not asystolic were eligible for inclusion. The
hospital protocol was not to give atropine routinely to children
aged over eight years, hence such cases were excluded. The
following data were prospectively recorded: age, sex, gestational
age (for births), pathology (neonatal respiratory distress [NRD],
non-neonatal respiratory distress [non-NRD], cardiac, neurolog-
ical, ear nose and throat [ENT], sepsis and ‘other’), principal
induction drug and atropine administration. The hospital proto-
cols for intra-venous intubation drugs were; atropine 20 mcg/kg,
etomidate 0.4 mg/kg, propofol 2–4 mg/kg, ketamine 1–2 mg/kg,
thiopental 5 mg/kg, morphine 0.1 mg/kg, midazolam 0.1 mg/kg,
sufentanyl 0.2 mcg/kg, suxamethonium 2 mg/kg less than 18
months and 1 mg/kg more than 18 months, vercuronium 0.1 mg/
kg. The PRISM III-24 (Paediatric RISk of Mortality) score was
recorded in the children .28 days [12].
Prescription of atropine was at the discretion of individual
intensivists. Those who received atropine were designated the
atropine group and comparisons were made to the no-atropine
group. Children who received atropine after the start of the
intubation as treatment of bradycardia were included in the no-
atropine group on the basis of the intention-not-to-treat.
The study population was divided a priori into two age sub-
groups, neonatal (#28 days post-natal age) and older children
(.28 days post-natal age and ,8 years), for the purposes of
analysis. The rationale to divide the group at this age was due to
the physiological transition in autonomic innervation that occurs
during early extra-uterine life [13] and due to the different
distribution of pathologies in the two groups.
Study Procedures
A one-minute ECG control strip (25 mm/s) was recorded prior
to the start of intubation, and used to calculate the mean pre-
intubation heart rate by averaging the lowest and highest heart
rate.
Continuous ECG/SpO2 recording started from the moment of
insertion of the laryngoscope until a SpO2 of $95% had been
obtained or the child connected to a ventilator. Two Paediatric
Intensivists reviewed the intubation ECGs independently and an
average was made of the two lowest, consecutive R-R intervals.
The number of attempts at intubation was recorded on the ECG
by the intensivist.
Propensity Score Construction
The propensity score (PS) is a one-dimensional summary of
multidimensional covariates that is used to make causal
inferences in observational studies by dealing with confounding
patient-specific prognostic characteristics that could have an
effect on both treatment assignment and outcome. The PS for a
group of patients is the sum of the probabilities for having
received a particular treatment according to a specified set of
pre-treatment covariates that might plausibly have affected
treatment assignment [14,15].
We constructed a PS for atropine prescription using the pre-
prescription variables (Table 1, with the exception of the PRISM
score) which included 10 or more children that had been identified
by a group of 61 Paediatric Intensivists in eight countries on three
continents as influencing their decision to prescribe atropine. [16]
Linearity in the log odds of continuous variables was assessed
visually and by using likelihood ratio testing.
End Points
Our primary end point was ICU mortality. The secondary end
points were the difference in heart rate from pre-intubation
baseline to the lowest two R-R complexes during intubation and
the number of days from intubation to death.
Statistical Analysis
Qualitative variables are described as numbers and percentages
and quantitative variables as median [quartiles] or mean (standard
deviation) according to their Gaussian distribution. Independent t-
tests or a Mann-Whitney test were used for continuous data
according to their distribution and Fisher’s exact test was used for
categorical data. All statistical tests were 2-sided and the
probability of a type 1 error (a) was determined at ,0.05.
Univariate and/or multivariable linear or logistic regression
models were constructed to test the effect of atropine using the
PS. Effect estimates were calculated for numerical variables and
odds ratios (OR) for categorical variables with their corresponding
95% confidence intervals (95%CI). Pearson correlation was used
to compare quantitative variables. Kaplan-Meier plots and Log-
rank tests were used for survival analysis. Missing data were
excluded list-wise. Statistical tests were carried out using SPSS
(version 19) with the exception of the PS which was performed
using SAS V.9.2 software (SAS, Cary, NC).
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Results
Study Patients and Atropine Use
A total of 333 children were eligible for inclusion of which 277
were included. Fifty-six children were not included and 13
children were excluded (Figure 1). A total of 264 study patients
were available for analysis (264/333, 79% [95%CI 75–83]) of
which 114 from PICU and 150 from ICT. Twenty-three
intensivists included a median of 5 [1–16] children each. Atropine
was prescribed in 124 of the 264 (47% [95%CI 41–53])
intubations. It was more frequently prescribed, although not
significantly (p = 0.08), during the intubations of neonates (79/153,
52% [95%CI 44–59]) than older children (45/111, 41% [95%CI
32–50]) (Table 1 and Figure 1). The median frequency of atropine
prescription per intensivist was 2 [1–8]. The PRISM score was
retrospectively available for 94 of 111 older children and was not
significantly (p = 0.09) different between the atropine and non-
atropine groups (Table 1).
Crude ICU Mortality
Thirty-one children died during ICT/ICU care (31/264,
12% [95%CI 8–16]). There was significantly lower mortality
(p = 0.003) in the neonatal group 7% (10/153 [95%CI 4–12])
than for the older children 19% (21/111 [95%CI 13–27]). No
children were lost to follow up. Only one child died during
intubation (aged 16 months with a lethal chromosomal disorder,
pulmonary hypertension and septic shock). This represents an
overall 0.4% [95%CI 0.07–2.1] mortality for the immediate
intubation period.
The unadjusted mortality prior to PICU discharge was 7% (9/
124 [95%CI 4–13]) for those who received atropine compared to
16% (22/140 [95%CI 11–23]) for those who did not (OR 0.42,
95%CI 0.19–0.95 p= 0.04). The median mortality estimated by
using the PRISM score was 8% [3–30] without atropine and 5%
[2–12] with atropine. The standardised mortality ratio (SMR)
between using the PRISM score as predictor of mortality (for the
94/111children for whom the score was available) was 1.05 for the
whole group and 1.16 for the no-atropine versus 0.74 for the
atropine groups. Ethomidate was used for 10 intubations, five with
and five without atropine. All the children who received atropine
survived with three deaths amongst those who did not receive
atropine. Atropine use was associated with a significant difference
in the survival of the older children (p= 0.005) but not neonates
(p = 0.57) (Figure 2). The excess mortality present in older children
with non-neonatal respiratory, cardiac and septic shock categories
(Table 2).
Table 1. Population characteristics for all patients and the two age sub-groups of neonates and older children.
All Patients (n =264) Neonates (n =153) Older children (n=111)
No-atropine
n=140(%)
Atropine
n=124(%)
No-atropine
n=74(%)
Atropine
n=79(%)
No-atropine
n=66(%)
Atropine
n=45(%)
Median age days [IQR] 21* [0–220] 1* [0–71] 0 [0–2] 0 [0–1] 225 [78–861] 134 [67–325]
Boys 94 (67) 85 (69) 56 (76) 60 (76) 38 (58) 25 (56)
Mean baseline heart rate,
min-1 (SD)
157* (133–181) 150* (125–175) 154 (132–176) 148 (126–170) 161 (135–187) 154 (124–184)
NRD 56 (40) 61 (49) 56 (76) 61 (77) – –
NonNRD 40 (29) 18 (15) 8 (11) 4 (5) 32 (48) 14 (31)
Cardiac 9 (6) 4 (3) 4 (5) 3 (4) 5 (8) 1 (2)
ENT 9 (6) 11 (9) 1 (1) 1 (1) 8 (12) 10 (22)
Neurologic 13 (9) 20 (16) 1 (1) 5 (6) 12 (18) 15 (33)
Sepsis 10 (7) 7 (6) 1 (1) 3 (4) 9 (14) 4 (9)
Other 3 (2) 3 (2) 3 (4) 2 (3) 0 (0) 1 (2)
No sedation drugs 35 (25) 37 (30) 30 (41) 35 (44) 5 (8) 2 (4)
Ethomidate 5 (4) 5 (4) 0 (0) 1 (1) 5 (8) 4 (9)
Propofol 44 (31) 23 (19) 10 (14) 2 (3) 34 (52) 21 (47)
Ketamine 12 (9) 3 (2) 0 (0) 0 (0) 12 (18) 3 (7)
Morphine 17 (12) 12 (10) 15 (20) 11 (14) 2 (3) 1 (2)
Midazolam 12 (9) 22 (18) 6 (8) 15 (19) 6 (9) 7 (16)
Sufentanyl 14 (10) 19 (15) 13 (18) 15 (19) 1 (2) 4 (9)
Other 1 (1) 3 (2) 0 (0) 0 (0) 1 (2) 3 (7)
Suxamethonium 8 (6) 3 (2) 0 (0) 0 (0) 8 (12) 3 (7)
Vecuronium 1 (1) 3 (2) 1 (1) 0 (0) 3 (5) 0 (0)
No-atropine (n = 57/66) Atropine (n = 37/45)
PRISM
n= 93
– – – – 10.5 [7–19] 9 [5–13.5]
All of the variables from the columns ‘All Patients’ were entered into the propensity score. the PRISM score was not used for the propensity score. Neonates are #28
days and older children .28 days and less than 8 years.
*p value ,0.05 for the difference between the atropine and non-atropine groups.
NRD - neonatal respiratory distress, Non-NRD - non-neonatal respiratory distress, ENT - ear nose and throat, PRISM - Paediatric RISk of Mortality score.
doi:10.1371/journal.pone.0057478.t001
Atropine for Paediatric Emergency Intubation
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e57478
Construction of the Propensity Score and Adjusted ICU
Mortality
Only two of the variables of baseline pre-atropine prescription
characteristics were significantly different between the atropine
and no-atropine groups, these were the median age of patients
(p = 0.02) and the mean baseline heart rate (p = 0.02). When the
two age sub-groups were further examined, there was no
significant difference between any of the variables. Three variables
were not included in the construction of the PS because they
featured in less than ten cases: fentanyl (n = 1), thiopental (n = 4)
and vecuronium (n= 4). The c-statistic of the PS was 0.72.
When the effect of atropine on mortality was examined in the
age subgroups using the PS there was a significant reduction of
mortality in the older children, but not in the neonates (Table 3).
We conducted a post hoc analysis to consider the apparent
association of atropine treatment with death by using two PS
constructed from the variables of each age group. This was done to
test the possibility that the construction of the PS from data from
all children would be different if the PS was constructed using data
from children of each age group. The association of atropine use
with death remained relatively unchanged: post hoc PS adjusted
OR in neonates of 2.4, (95%CI 0.56–10.4, p= 0.23) and post hoc
PS adjusted OR 0.24 (95%CI 0.06–0.96, p= 0.043) for the older
children (see Table 3).
Details of the Intubations
Measured oxygen saturations were similar between atropine
and non-atropine groups. Median fall in SpO2 was 25% [8–44] in
the non-atropine group and 19% [6–44] in the atropine group
(p = 0.31). There was a significant correlation between a fall in
SpO2 and a fall in heart rate (p,0.0001) (Figure 3 and Table 4).
The median number of attempts at intubation was also
comparable between non-atropine (1 [1–2]) and atropine (1 [1–
2]) (p = 0.20) cases. One attempt at intubation significantly
reduced mean heart rate in the neonates by 9.6 beats-per-minute
(bpm) (95%CI 2.3–16.9, p = 0.01) but not in the older children
(6.1 bpm per intubation attempt, 95%CI 1.5–13.8, p = 0.12).
Eleven children were excluded from the saturation analysis and 16
from the number of attempts at intubation because of missing
data.
Adjusted Change in Heart Rate
The use of the PS had little effect on the crude estimates of the
mean change in heart rate (Figure 4) which was 58.7 bpm without
the PS versus 53.4 bpm with the PS for the neonates and 41.5 bpm
without the PS versus 40.8 bpm with the PS for the older children.
The PS adjusted changes in heart rate due to changes in SpO2
and attempts at intubation are shown in Table 4.
Discussion
We disproved our hypothesis and showed that the use of
atropine was associated with a lower overall ICU mortality. This
result is unrelated to any effect on intubation bradycardia which
occurred in a similar measure in both age groups when atropine
was not used.
Our population was diverse with 57% of children being
intubated and hospitalised outside the PICU of Robert Debre´.
Atropine was used in 47% of our cases. This is similar to a 2004
survey in 204 French PICUs [17] and a 2010 report from UK
neonatal units. [18] A recent survey of influences on atropine use
and atropine prescribing habits among 61 paediatric intensivists in
8 countries noted that 49% prescribed atropine for half of their
Figure 1. Flow-chart of inclusions, non-inclusions and exclusions. Neonates are#28 days and older children.28 days and less than
8 years. *ICT - Intensive Care Transport team positioned antenatally for premature births.
doi:10.1371/journal.pone.0057478.g001
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intubations. [16] One area where our practice differs from others
is the relatively infrequent use of muscle relaxants including
suxamethonium. This is due to several reasons; firstly the large
proportion of neonates for whom our hospital protocol does not
recommend muscle paralysis, secondly, a relatively large propor-
tion of ENT intubations and finally the high proportion of
propofol use which is associated with good intubation conditions
without relaxants [19].
When we compare the intubation conditions in our study
population with published series, the number of intubation
attempts were equivalent to existing neonatal [20,21] and
paediatric studies. [3,4] Similarly, median trough SpO2 values
for the neonates (76%) were consistent with previously published
values (58–80%). [18,20,21] In PICU Carroll et al. [3] noted that
peripheral desaturation below 90% occurred in 29% of intuba-
tions (40/137) and in the Emergency Department, Fastle and
Roback recorded an incidence of 22% (31/143). [4] If we use an
identical definition for our study population, as many as 75% of
the children were desaturated. Nevertheless, neither of these
studies recorded median fall in saturation and both reflected on
the bias inherent in their retrospective, self-reporting methodol-
ogies.
The mortality in our intubated study population of older
children was 19% (SMR 1.05 using the PRISM score as a
mortality predictor) which compares to 8.3% mortality for
emergency admissions and 3.7% overall mortality in PICU for
all ages during the study period. This contrasts to 4.8% PICU
mortality for children under 10 years in Great Britain and Ireland
for the years 2007–9 [22].
The propensity score is a valuable tool for analysing differences
in drug effect in non-randomised studies where selection bias may
be important. [23] We chose a multivariable regression based
model which provides more statistical power. [24] Our study
design produced treatment groups of neonates and older children
Figure 2. Kaplan-Meier plots for mortality in the two age sub-
groups of neonates and older children.
doi:10.1371/journal.pone.0057478.g002
Table 2. Breakdown of the causes of death by pathology. Neonates are #28 days and older children .28 days and less than 8
years.
Neonates (n =153, deaths/cases) Older children (n =111, deaths/cases)
Non-atropine n=74(n%) Atropine n=79(n%)
Non-atropine
n=66(n%) Atropine n=45(n%)
Neonatal respiratory distress 1/56(2) 2/61 (3) – –
Non-neonatal respiratory distress 2/8 (3) 0/4 (0) 9/32 (14) 0/14 (0)
Cardiac 0/4 (0) 0/3 (0) 2/5 (3) 0/1 (0)
Ear, nose and throat 1/1 (1) 0/1 (0) 1/8 (2) 0/10 (0)
Neurologic 0/1 (0) 3/5 (4) 3/12 (5) 3/15 (7)
Sepsis 0/1 (0) 1/3 (1) 3/9 (5) 0/4 (0)
Other 0/3 (0) 0/2 (0) 0/0 (0) 0/1 (0)
Total 4 (5) 6 (8) 18 (27) 3 (7)
doi:10.1371/journal.pone.0057478.t002
Table 3. ICU mortality related to atropine use corrected by
the propensity score (PS) in the two age subgroups. Neonates
are #28 days of age and older children .28 days and less
than 8 years.
Neonates (n =153) Older children (n=111)
Odds
ratio P CI 95%
Odds
ratio p CI 95%
Atropine crude
mortality
1.4 0.59 0.39, 5.3 0.21 0.017 0.06, 0.75
Atropine PS
corrected
1.3 0.74 0.31, 5.1 0.22 0.028 0.06, 0.85
doi:10.1371/journal.pone.0057478.t003
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where there were no significant differences between pre-treatment
variables (Table 1). This validates the use of the PS for which a
considerable overlap in the distribution of variables is an a priori
condition. In addition, our result for the crude OR for the ICU
mortality in the older children (0.21) remained stable when
adjusted using an all-patients PS (0.22) and when using a post hoc
older children PS (0.24). Despite our result remaining significant
when using a PS for all patients and divided for the two age
groups, our findings need to be confirmed in a study using
randomised methodology.
There are three possible explanations for the unexpected
significant difference in ICU mortality with and without atropine.
Firstly, the PS has not dealt with atropine prescription bias
because not all prescription-influencing co-variates were included
in its construction, which is a condition of its use. [14] This means
that residual confounders remained after using the PS which
linked atropine prescription to death. A possible indication of this
could be the non-significant difference in the PRISM scores and
SMR of the atropine and non-atropine groups, which showed a
trend towards an increased risk of death for the non-atropine
group. The significant difference in the baseline heart rate between
the two groups is integrated in the PRISM score but was also
included in the PS before adjusting the final result. Secondly, that
chance has produced a statistically significant result and finally
that the effect of atropine in reducing mortality is real.
The excess mortality we observed was not related to mortality
during intubation because this was rare with only a single death
observed. Neither can the excess post-intubation mortality be
ascribed to a late effect of bradycardia because this occurred with
similar frequency in both the neonates and older children (Table 4
and Figure 4) yet the ICU mortality difference was only seen in the
older children.
One possible explanation for the observed effect of atropine on
mortality may be related the uncoupling of real-time feedback of
measurements of blood pressure in the baroreceptors in the carotid
bodies, which has the effect of reducing R-R beat-to-beat
variability (RRBBV). Vagal impulses are rapid by nature of the
rapid hydrolysation of acetylcholine in postganglionic parasym-
pathetic receptors contrary to sympathetic stimulation of the heart
and vessels which is of the order of 2–5 seconds. [25] Reductions
in RRBBV following atropine administration have been measured
in premature neonates awaiting intubation for respiratory distress
[26] and normal children undergoing routine anaesthesia. [27] In
small children, reductions in RRBBV could be achieved by a
single dose of atropine due to its long half-life [28] which is a
consequence of the extended elimination phase resulting from its
increased distribution volume [29].
Pre-terminal haemodynamic decompensation is frequently
accompanied by bradycardia in children. [30] It results from a
‘two-hit’ process whereby the first step is often exaggerated
RRBBV before the second step of entry into a negative feedback
loop of arrhythmia and hypoperfusion, as has been demonstrated
experimentally in dogs. [31] The short-lived intubation bradycar-
dia commonly observed in our non-atropinised patients is an
example of severe RRBBV, yet intubation mortality was rare
because the children were still self-protecting from the second step
of bradycardia-hypoperfusion. Atropine is ineffective against hypo-
perfusion and non-vagally mediated bradycardia when they are
already established, indeed atropine is no longer recommended by
the AHA for resuscitation. [32] However, when atropine is
prophylactically administered before bradycardia-hypoperfusion,
as happened to our atropinised older patients, some of whom later
became vulnerable to haemodynamic decompensation, atropine
could protect against the first step of spontaneously occurring
exaggerated RRBBV.
Despite the prolonged half-life of atropine in the young, as
mentioned above, the protection accorded is unlikely to be
responsible for the entirety of the reduction observed in mortality
in the older children because the many of these deaths occurred
more than several days after intubation (Figure 2).
Figure 3. The change in heart rate related to a change in
peripheral oxygen saturation (SpO2) during intubation.
doi:10.1371/journal.pone.0057478.g003
Table 4. Multivariable analysis of the change in heart rate during intubation following fall in peripheral oxygen saturation (SpO2)
and after the use of atropine (corrected by the propensity score [PS]). Neonates are#28 days and older children.28 days and less
than 8 years.
Neonates (n =153) Older children (n =111)
Heart rate change
(bpm) P CI 95%
Heart rate change
(bpm) p CI 95%
Fall in SpO2 by 10% points 24.1 0.005 21.3, 27.0 25.4 ,0.001 22.6, 28.4
Difference with and without
atropine (PS corrected)
245.9 ,0.001 234.3, 257.5 243.5 ,0.001 225.5, 261.5
doi:10.1371/journal.pone.0057478.t004
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Conclusions
Atropine was associated with a reduction in ICU mortality
outside the immediate period of the intubation only in children
aged over one month. This effect is independent of its capacity to
reduce heart slowing during intubation. The association between
atropine use during CCI and reduced ICU mortality should be
investigated in other populations using a randomised methodol-
ogy.
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